Navigation Links
Goodwin Biotechnology was Selected by Panacea Pharmaceuticals for a Highly Specialized Vaccine Fill / Finish Project
Date:5/11/2015

PLANTATION, Fla., May 11, 2015 /PRNewswire/ -- Goodwin Biotechnology, Inc., a biological Contract Development and Manufacturing Organization (CDMO) that specializes in bioprocess development and GMP manufacturing of biopharmaceuticals utilizing Mammalian Cell Culture expression systems and Bioconjugation technologies, was selected by Panacea Pharmaceuticals, Inc. to complete a novel Fill / Finish project, as well as Quality Control release and stability testing for a therapeutic, nanoparticle cancer vaccine based on the Human Aspartyl (Asparaginyl) β-Hydroxylase (HAAH) tumor-specific protein to support Phase I clinical trials in patients with various solid tumor cancers.

"Over the last year, we partnered with Goodwin Biotechnology on a bioconjugation project and have found them to be extremely responsive and flexible. They had an innovative approach to address some rather significant challenges in an effort to move our project forward," noted Dr. Steven A. Fuller, Ph.D., Chief Operating Officer at Panacea Pharmaceuticals. "When we identified the need to select a company for our Fill / Finish project that involves a unique injector cartridge filling procedure for our other lead compound, we evaluated Goodwin's capabilities and we were pleased to find out that their approach to niche Fill / Finish projects was just as flexible and solutions oriented. When coupling that with the sophistication of their quality system they've put in place and the technical expertise of their staff, the decision became obvious."

"We are pleased to have Panacea Pharmaceuticals work with us on their two lead compounds," said SooYoung S. Lee, Ph.D., Chief Operating Officer at Goodwin Biotechnology. "While being selected for a Bioconjugation or Cell Culture-based project is typical, based on the many years of successful track records and our commitment to bring advances to those fields, it is more rewarding to know that our investment to build and offer the comprehensive infrastructure required to deliver ready-for-clinical-trials, Final Vialed Product (FVP) and provide integrated solutions to meet specific and unique requirements of our clients has been helpful for Panacea. Our staff takes great pride in their respective skill sets and, as a team, we all place a great level of emphasis on quality and being responsive to our client's needs to enhance the value of our clients' drug candidates." 

Goodwin Biotechnology operates an ISO5 cGMP filling suite that can accommodate liquid filling of a wide range of configurations to meet specific and unique clients' requirements.  For more than 20 years, Goodwin Biotechnology has been manufacturing Bulk Drug Substance and performing Fill / Finish services for small startup ventures to large, multi-national companies as well as government agencies and medical institutions. Goodwin has successfully completed numerous traditional Fill / Finish and Drug Product manufacturing projects, as well as customized, specialized Fill / Finish projects for small volume fills, light sensitive products, and extremely fragile biological drugs for which large-scale, automated fill systems are not appropriate.   

About Goodwin Biotechnology, Inc.
Goodwin Biotechnology is a uniquely qualified CDMO that offers a Single Source Solution™ for our  clients from cell line development,  exploratory proof of concept projects through process development and cGMP contract manufacturing of monoclonal antibodies, recombinant proteins, vaccines, and Biologic Drug Conjugates including Antibody Drug Conjugates (ADCs) for early and late stage clinical trials. By working with Goodwin Biotechnology, clients can enhance the value of their product candidates with clear development and manufacturing strategies, as well as a road map to meet the appropriate quality requirements from the milligram and gram range to kilogram quantities as the product candidates move along the clinical development pathway in a cost-effective, timely, and cGMP compliant manner to enhance patients' lives. With over 20 years of experience as an independent integrated contract manufacturer, Goodwin Biotechnology has worked as a strategic partner with companies of all sizes from small university spin-offs to major research institutes, government agencies and large, established and multi-national biopharmaceutical companies. Based on the impressive track record, Goodwin Biotechnology was recently awarded Frost & Sullivan's Customer Value and Leadership Award for Best Practices in Mammalian Contract Manufacturing!  Additional information may be found at http://www.GoodwinBio.com.

About Panacea Pharmaceuticals, Inc.
Panacea Pharmaceuticals, Inc. was founded in 1999 to discover, develop, and commercialize novel therapeutic and diagnostic products for oncology and diseases of the central nervous system. Since its inception, the Company's primary approach to cancer treatment has been immunotherapy and development of companion diagnostics for comprehensive patient management. The Company's lead drug product candidate is a nanoparticle-based therapeutic cancer vaccine that targets a novel patented tumor-specific protein, Human Aspartyl (Asparaginyl) beta-Hydroxylase (HAAH). The company enjoys a close collaboration with Brown University/Rhode Island Hospital in Providence, Rhode Island where teams of researchers are continuing advances on the Company's core technologies. For more information, visit the company's Web site at www.panaceapharma.com.

For more information, please contact:

Goodwin Biotechnology:

Robin McCallum, M.Sc.

Business Development Manager

(954) 327-9656

RMcCallum@GoodwinBio.com
       or
Info@GoodwinBio.com  

Panacea Pharmaceuticals:

Steven A. Fuller, Ph.D.

Chief Operating Officer

(240) 454-8010

SFuller@panaceapharma.com

 


'/>"/>
SOURCE Goodwin Biotechnology, Inc.
Copyright©2015 PR Newswire.
All rights reserved

Related medicine technology :

1. Goodwin Biotechnology Announces the Appointment of SooYoung S. Lee, PhD as Chief Operating Officer
2. Goodwin Biotechnology Announces Process Development Sub-Contract for an Anthrax Vaccine
3. Portal Instruments Adds Two Esteemed Biotechnology Leaders to its Scientific Advisory Board
4. TaiGen Biotechnology Announces Initiation of Burixafor Chemosensitization Clinical Trial in Acute Myeloid Leukemia in China
5. Mid-Cap Biotechnology Benchmark Report - Sales Forecasts and Product Valuations of Innovative Biotechs
6. Leukemia Research Funded by The Leukemia & Lymphoma Society Gets Infusion of Support from Startup Biotechnology Company
7. Marine Biotechnology - Global Strategic Business Report 2015-2020: Polysaccharides from Marine Microalgae Holds Tremendous Potential
8. TaiGen Biotechnology Announces Burixafor Collaboration with Cellex and the University Hospital Carl Gustav Carus Dresden in Germany
9. TWi Biotechnology Receives Rare Disease Drug Designation for its Drug Candidate AC-203 in Taiwan
10. First Gathering of Biotech Experts Aims to Establish Ethical Standards in Cellular Biotechnology at BEINGS 2015
11. Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/17/2019)... ... July 17, 2019 , ... Highmark Health, Allegheny Health ... enthusiasts from around the region to announce plans for what will be one of ... in Coraopolis on State Avenue and adjacent to the Montour Trail, the complex is ...
(Date:7/17/2019)... ... ... The American Psychiatric Nurses Association (APNA) is pleased to announce the ... by psychiatric-mental health nurse members from across the country, these six individuals will begin ... October 2-5, 2019. , “These new members of the Board of Directors and Nominating ...
(Date:7/17/2019)... ... July 17, 2019 , ... Halcyon, one of ... its payment processor of record. , As a result of the partnership, ... platform can now also accept and process payments through it, securely and easily. ...
Breaking Medicine Technology:
(Date:7/18/2019)... ... July 18, 2019 , ... We are pleased ... Texas Monthly Super Doctor Rising Star ! Each year, Texas Monthly ... trust for their own medical care. The Super Doctors research team then investigates ...
(Date:7/17/2019)... ... July 17, 2019 , ... The FDA has cleared the ... treating up to eight body areas simultaneously. Dr. Dennis Dass says the ... and easier than previous muscle toning devices or conventional exercise. , “The truSculpt® flex ...
(Date:7/17/2019)... (PRWEB) , ... July 17, 2019 , ... In order ... which damage to the teeth could occur, from the accident scene, to the moment ... and created a paradigm shift for treatment. , They identified seven points, so called ...
(Date:7/17/2019)... ... 2019 , ... Dynamic Healthcare Systems, a leading ... Marketplace programs is pleased to announce the introduction of an expanded Risk ... at the point of care to providers and provider groups participating in value-based ...
(Date:7/17/2019)... ... July 17, 2019 , ... It took just several ... Carlos Martinez, MD, to relieve pressure on the nerves under Amber Walck’s scalp, and ... PA woman turned 30 last year, her debilitating headaches began without warning. About ...
Breaking Medicine News(10 mins):